Concepts (295)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Angiopathies | 33 | 2010 | 203 | 2.990 |
Why?
|
| Aspirin | 28 | 2010 | 295 | 2.770 |
Why?
|
| Diabetes Mellitus | 36 | 2010 | 694 | 2.110 |
Why?
|
| Platelet Aggregation Inhibitors | 16 | 2010 | 373 | 1.840 |
Why?
|
| Diabetes Mellitus, Type 2 | 30 | 2010 | 1085 | 1.580 |
Why?
|
| Cardiovascular Diseases | 15 | 2010 | 940 | 1.400 |
Why?
|
| Insulin | 37 | 2000 | 619 | 1.280 |
Why?
|
| Blood Platelets | 25 | 2003 | 284 | 1.100 |
Why?
|
| Diabetes Complications | 13 | 2010 | 249 | 0.950 |
Why?
|
| Blood Glucose | 30 | 2000 | 631 | 0.730 |
Why?
|
| Hypoglycemic Agents | 16 | 2001 | 362 | 0.660 |
Why?
|
| Arteriosclerosis | 11 | 1997 | 137 | 0.560 |
Why?
|
| Diabetes Mellitus, Type 1 | 10 | 1997 | 529 | 0.440 |
Why?
|
| Platelet Aggregation | 18 | 1995 | 127 | 0.400 |
Why?
|
| Humans | 97 | 2010 | 68618 | 0.350 |
Why?
|
| Gangrene | 5 | 1989 | 11 | 0.340 |
Why?
|
| Coronary Disease | 3 | 2010 | 358 | 0.320 |
Why?
|
| Dipyridamole | 6 | 1989 | 26 | 0.320 |
Why?
|
| Diabetic Neuropathies | 4 | 2006 | 33 | 0.300 |
Why?
|
| Thrombosis | 4 | 1997 | 218 | 0.300 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 3 | 2001 | 58 | 0.290 |
Why?
|
| Diabetic Foot | 1 | 2007 | 33 | 0.290 |
Why?
|
| Atherosclerosis | 1 | 2009 | 204 | 0.280 |
Why?
|
| Diabetic Retinopathy | 7 | 1998 | 110 | 0.270 |
Why?
|
| Hyperglycemia | 5 | 1997 | 158 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 5 | 2010 | 772 | 0.210 |
Why?
|
| Triglycerides | 8 | 1998 | 184 | 0.200 |
Why?
|
| Ischemia | 1 | 2003 | 229 | 0.200 |
Why?
|
| Blood Coagulation Disorders | 1 | 2001 | 45 | 0.200 |
Why?
|
| Gliclazide | 2 | 1991 | 2 | 0.200 |
Why?
|
| Fibrinolysis | 5 | 2001 | 55 | 0.190 |
Why?
|
| South Carolina | 7 | 2008 | 2752 | 0.190 |
Why?
|
| Male | 46 | 2008 | 37321 | 0.190 |
Why?
|
| Lipoproteins, LDL | 6 | 1988 | 343 | 0.190 |
Why?
|
| Glipizide | 6 | 1998 | 7 | 0.180 |
Why?
|
| Reimbursement Mechanisms | 1 | 2000 | 37 | 0.180 |
Why?
|
| Hospitals, Veterans | 7 | 1999 | 147 | 0.180 |
Why?
|
| Arachidonic Acids | 7 | 1985 | 97 | 0.170 |
Why?
|
| Legislation, Medical | 1 | 1998 | 8 | 0.160 |
Why?
|
| Middle Aged | 34 | 2010 | 21147 | 0.160 |
Why?
|
| Homocysteine | 1 | 1997 | 28 | 0.150 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 198 | 0.150 |
Why?
|
| Adult | 31 | 2007 | 21403 | 0.140 |
Why?
|
| Preventive Health Services | 1 | 1997 | 86 | 0.140 |
Why?
|
| United States | 12 | 2010 | 7367 | 0.130 |
Why?
|
| Lipids | 6 | 1998 | 298 | 0.130 |
Why?
|
| Clinical Trials as Topic | 8 | 1998 | 848 | 0.130 |
Why?
|
| Linear Models | 2 | 2008 | 521 | 0.130 |
Why?
|
| Risk Factors | 9 | 2010 | 5731 | 0.130 |
Why?
|
| C-Peptide | 4 | 1998 | 23 | 0.130 |
Why?
|
| Fibrinogen | 2 | 1998 | 87 | 0.130 |
Why?
|
| Aged | 17 | 2010 | 14862 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 2 | 2006 | 57 | 0.120 |
Why?
|
| Female | 24 | 2010 | 38074 | 0.120 |
Why?
|
| Primary Prevention | 2 | 2010 | 115 | 0.120 |
Why?
|
| Patient Education as Topic | 3 | 2007 | 425 | 0.110 |
Why?
|
| Gemfibrozil | 1 | 1993 | 4 | 0.110 |
Why?
|
| Anesthesia, Inhalation | 1 | 1992 | 9 | 0.110 |
Why?
|
| Isoflurane | 1 | 1992 | 16 | 0.110 |
Why?
|
| Albuminuria | 5 | 2006 | 171 | 0.110 |
Why?
|
| Swine, Miniature | 1 | 1992 | 45 | 0.110 |
Why?
|
| Lipoproteins | 5 | 1998 | 161 | 0.110 |
Why?
|
| Metformin | 1 | 1993 | 63 | 0.110 |
Why?
|
| Cholesterol | 8 | 1998 | 331 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 1993 | 90 | 0.100 |
Why?
|
| Drug Therapy, Combination | 5 | 2004 | 649 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 1745 | 0.100 |
Why?
|
| Hospitalization | 2 | 2008 | 978 | 0.100 |
Why?
|
| von Willebrand Factor | 9 | 1983 | 47 | 0.090 |
Why?
|
| Prevalence | 3 | 2007 | 1619 | 0.090 |
Why?
|
| Plasminogen | 1 | 1990 | 28 | 0.090 |
Why?
|
| Death, Sudden | 1 | 1989 | 24 | 0.090 |
Why?
|
| Physical Exertion | 1 | 1990 | 75 | 0.090 |
Why?
|
| Fibronectins | 1 | 1990 | 130 | 0.090 |
Why?
|
| Arachidonic Acid | 6 | 1985 | 86 | 0.080 |
Why?
|
| Voluntary Health Agencies | 1 | 1988 | 4 | 0.080 |
Why?
|
| Glucose Tolerance Test | 9 | 1992 | 75 | 0.080 |
Why?
|
| Insulin Infusion Systems | 2 | 1985 | 27 | 0.080 |
Why?
|
| Diabetic Nephropathies | 3 | 2006 | 161 | 0.080 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2008 | 36 | 0.070 |
Why?
|
| International Classification of Diseases | 1 | 2007 | 85 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2007 | 274 | 0.070 |
Why?
|
| Sulfonylurea Compounds | 4 | 2000 | 17 | 0.070 |
Why?
|
| Epoprostenol | 5 | 1985 | 71 | 0.070 |
Why?
|
| Platelet Adhesiveness | 4 | 1980 | 20 | 0.070 |
Why?
|
| Urban Population | 1 | 2007 | 255 | 0.070 |
Why?
|
| Blood Coagulation Factors | 4 | 1980 | 44 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2006 | 223 | 0.070 |
Why?
|
| Health Surveys | 1 | 2007 | 489 | 0.060 |
Why?
|
| In Vitro Techniques | 4 | 1995 | 765 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2008 | 622 | 0.060 |
Why?
|
| Reference Values | 3 | 1995 | 579 | 0.060 |
Why?
|
| Glucose | 6 | 1983 | 307 | 0.060 |
Why?
|
| Length of Stay | 1 | 2008 | 780 | 0.060 |
Why?
|
| Rural Population | 1 | 2007 | 398 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 378 | 0.060 |
Why?
|
| Drug Administration Schedule | 4 | 2000 | 567 | 0.060 |
Why?
|
| Feasibility Studies | 5 | 1998 | 652 | 0.060 |
Why?
|
| Kallikreins | 1 | 1984 | 323 | 0.050 |
Why?
|
| Cholesterol, HDL | 3 | 1995 | 112 | 0.050 |
Why?
|
| Apolipoproteins | 1 | 1983 | 51 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2010 | 7029 | 0.050 |
Why?
|
| Safety | 1 | 2003 | 145 | 0.050 |
Why?
|
| Cholesterol, LDL | 3 | 1995 | 161 | 0.050 |
Why?
|
| Endothelium, Vascular | 3 | 1991 | 371 | 0.050 |
Why?
|
| Thromboxane B2 | 4 | 1988 | 108 | 0.050 |
Why?
|
| Adenosine Diphosphate | 7 | 1985 | 66 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2003 | 177 | 0.050 |
Why?
|
| Random Allocation | 3 | 1989 | 442 | 0.050 |
Why?
|
| Fibroblasts | 2 | 1985 | 902 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2008 | 4848 | 0.040 |
Why?
|
| beta-Thromboglobulin | 2 | 1994 | 7 | 0.040 |
Why?
|
| Pheochromocytoma | 2 | 1969 | 22 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 931 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 240 | 0.040 |
Why?
|
| American Heart Association | 2 | 2010 | 142 | 0.040 |
Why?
|
| Prognosis | 2 | 2010 | 2093 | 0.040 |
Why?
|
| Blood Pressure | 5 | 2000 | 1451 | 0.040 |
Why?
|
| Platelet Activating Factor | 1 | 1979 | 34 | 0.040 |
Why?
|
| Governing Board | 1 | 1998 | 12 | 0.040 |
Why?
|
| Risk | 1 | 1999 | 563 | 0.040 |
Why?
|
| Animals | 11 | 1995 | 20881 | 0.040 |
Why?
|
| Tablets, Enteric-Coated | 1 | 1997 | 2 | 0.040 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1997 | 40 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2010 | 403 | 0.040 |
Why?
|
| Schools, Medical | 1 | 1998 | 157 | 0.040 |
Why?
|
| Program Development | 1 | 1998 | 240 | 0.040 |
Why?
|
| Myocardial Infarction | 3 | 1989 | 807 | 0.040 |
Why?
|
| Body Mass Index | 2 | 1998 | 867 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2000 | 481 | 0.040 |
Why?
|
| Placebos | 1 | 1997 | 195 | 0.040 |
Why?
|
| Epinephrine | 5 | 1981 | 103 | 0.030 |
Why?
|
| Research | 3 | 1998 | 214 | 0.030 |
Why?
|
| Administration, Oral | 2 | 1996 | 411 | 0.030 |
Why?
|
| Morbidity | 1 | 1996 | 130 | 0.030 |
Why?
|
| Cost of Illness | 1 | 1997 | 206 | 0.030 |
Why?
|
| Treatment Failure | 1 | 1996 | 216 | 0.030 |
Why?
|
| Disease Management | 1 | 1997 | 248 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 1993 | 1738 | 0.030 |
Why?
|
| Thromboxane A2 | 2 | 1985 | 88 | 0.030 |
Why?
|
| Cholesterol, VLDL | 1 | 1995 | 17 | 0.030 |
Why?
|
| 5,8,11,14-Eicosatetraynoic Acid | 1 | 1975 | 1 | 0.030 |
Why?
|
| Platelet Activation | 1 | 1995 | 24 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 504 | 0.030 |
Why?
|
| Factor V | 1 | 1975 | 20 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1975 | 84 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1996 | 202 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1997 | 185 | 0.030 |
Why?
|
| Biomarkers | 2 | 1998 | 1593 | 0.030 |
Why?
|
| Diet, Diabetic | 1 | 1994 | 14 | 0.030 |
Why?
|
| Apolipoproteins A | 2 | 1985 | 10 | 0.030 |
Why?
|
| Platelet Factor 4 | 1 | 1994 | 10 | 0.030 |
Why?
|
| Growth Hormone | 3 | 1980 | 51 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 2 | 1986 | 182 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 3 | 1985 | 48 | 0.030 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2000 | 62 | 0.030 |
Why?
|
| Health Behavior | 1 | 1997 | 458 | 0.030 |
Why?
|
| Logistic Models | 1 | 1997 | 1420 | 0.030 |
Why?
|
| Adipose Tissue | 2 | 1972 | 221 | 0.030 |
Why?
|
| Lipoproteins, VLDL | 2 | 1983 | 32 | 0.030 |
Why?
|
| Phentolamine | 2 | 1971 | 8 | 0.030 |
Why?
|
| Adolescent | 6 | 1988 | 8912 | 0.030 |
Why?
|
| Pancreas | 3 | 1968 | 225 | 0.030 |
Why?
|
| Prostaglandins | 3 | 1980 | 65 | 0.030 |
Why?
|
| Hypoxanthines | 1 | 1972 | 6 | 0.030 |
Why?
|
| Xanthines | 1 | 1972 | 17 | 0.030 |
Why?
|
| Lipoproteins, HDL | 2 | 1983 | 113 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1995 | 1040 | 0.030 |
Why?
|
| Metabolism, Inborn Errors | 1 | 1972 | 19 | 0.030 |
Why?
|
| Catecholamines | 2 | 1969 | 73 | 0.030 |
Why?
|
| Uric Acid | 1 | 1972 | 37 | 0.030 |
Why?
|
| Fatty Acids | 2 | 1963 | 222 | 0.030 |
Why?
|
| Lipomatosis | 1 | 1972 | 4 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 1972 | 23 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 1991 | 10 | 0.020 |
Why?
|
| Factor VIII | 2 | 1983 | 27 | 0.020 |
Why?
|
| Follow-Up Studies | 4 | 2000 | 3259 | 0.020 |
Why?
|
| Swine | 1 | 1992 | 672 | 0.020 |
Why?
|
| Stroke | 1 | 2004 | 2163 | 0.020 |
Why?
|
| Time Factors | 5 | 2000 | 4655 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 1971 | 72 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 1985 | 2673 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1969 | 26 | 0.020 |
Why?
|
| Child | 4 | 1985 | 6405 | 0.020 |
Why?
|
| Quality of Life | 1 | 1998 | 1515 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1995 | 2358 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1971 | 163 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 186 | 0.020 |
Why?
|
| Fund Raising | 1 | 1988 | 6 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 1988 | 58 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 507 | 0.020 |
Why?
|
| Adenoma, Islet Cell | 1 | 1968 | 2 | 0.020 |
Why?
|
| Parathyroid Neoplasms | 1 | 1968 | 13 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 1980 | 73 | 0.020 |
Why?
|
| History, 20th Century | 1 | 1988 | 248 | 0.020 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1968 | 39 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1971 | 334 | 0.020 |
Why?
|
| Sulfanilamides | 2 | 1957 | 2 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1990 | 296 | 0.020 |
Why?
|
| Education, Medical | 1 | 1988 | 147 | 0.020 |
Why?
|
| Endothelium | 2 | 1983 | 98 | 0.020 |
Why?
|
| Insulin Resistance | 3 | 1998 | 241 | 0.020 |
Why?
|
| Sensation | 1 | 2006 | 49 | 0.020 |
Why?
|
| Receptors, Lipoprotein | 1 | 1985 | 11 | 0.020 |
Why?
|
| Prospective Studies | 3 | 1998 | 3705 | 0.020 |
Why?
|
| Phosphatidylethanolamines | 1 | 1985 | 20 | 0.020 |
Why?
|
| Hypertension | 1 | 1995 | 1535 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 1985 | 38 | 0.020 |
Why?
|
| Sulfonamides | 2 | 1957 | 141 | 0.020 |
Why?
|
| Culture Media | 1 | 1985 | 155 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2006 | 208 | 0.020 |
Why?
|
| Diuresis | 1 | 1984 | 20 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1985 | 248 | 0.010 |
Why?
|
| Aldosterone | 1 | 1984 | 51 | 0.010 |
Why?
|
| Prediabetic State | 3 | 1977 | 48 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1968 | 332 | 0.010 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1984 | 45 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1985 | 157 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 1986 | 307 | 0.010 |
Why?
|
| Lipoproteins, IDL | 1 | 1983 | 8 | 0.010 |
Why?
|
| Plasminogen Activators | 1 | 1983 | 19 | 0.010 |
Why?
|
| Collagen | 3 | 1976 | 636 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2007 | 0.010 |
Why?
|
| Carbohydrate Metabolism | 1 | 1963 | 20 | 0.010 |
Why?
|
| Fasting | 2 | 1998 | 75 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1983 | 54 | 0.010 |
Why?
|
| Antigens | 1 | 1983 | 90 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1963 | 43 | 0.010 |
Why?
|
| Portal Vein | 1 | 1963 | 46 | 0.010 |
Why?
|
| Coccidioidomycosis | 2 | 1961 | 6 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 1983 | 29 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1963 | 215 | 0.010 |
Why?
|
| Tolbutamide | 3 | 1975 | 5 | 0.010 |
Why?
|
| Prostanoic Acids | 1 | 1981 | 9 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 2000 | 6 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1981 | 175 | 0.010 |
Why?
|
| Creatinine | 1 | 2000 | 243 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1981 | 314 | 0.010 |
Why?
|
| Research Design | 1 | 1984 | 729 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1983 | 1054 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1959 | 26 | 0.010 |
Why?
|
| Dogs | 3 | 1966 | 490 | 0.010 |
Why?
|
| Kinetics | 1 | 1981 | 1047 | 0.010 |
Why?
|
| Sex Factors | 1 | 1983 | 1266 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 1959 | 108 | 0.010 |
Why?
|
| Imidazoles | 1 | 1979 | 175 | 0.010 |
Why?
|
| Rats | 2 | 1980 | 5300 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1980 | 195 | 0.010 |
Why?
|
| Smoking | 2 | 1996 | 1452 | 0.010 |
Why?
|
| Liver | 1 | 1963 | 1118 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1977 | 35 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1977 | 94 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1983 | 3187 | 0.010 |
Why?
|
| Hospitals, Animal | 1 | 1995 | 2 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1976 | 73 | 0.010 |
Why?
|
| Peroxides | 1 | 1975 | 23 | 0.010 |
Why?
|
| Quality Control | 1 | 1995 | 81 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1997 | 792 | 0.010 |
Why?
|
| Exercise | 1 | 2000 | 658 | 0.010 |
Why?
|
| Pregnancy | 1 | 1980 | 2334 | 0.010 |
Why?
|
| Diet Therapy | 1 | 1972 | 22 | 0.010 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1972 | 9 | 0.010 |
Why?
|
| Glycogen Storage Disease | 1 | 1971 | 1 | 0.010 |
Why?
|
| Gluconeogenesis | 1 | 1971 | 7 | 0.010 |
Why?
|
| Glucagon | 1 | 1971 | 22 | 0.010 |
Why?
|
| Feedback | 1 | 1972 | 90 | 0.010 |
Why?
|
| Lactates | 1 | 1971 | 29 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2000 | 1034 | 0.010 |
Why?
|
| Phosphates | 1 | 1971 | 72 | 0.010 |
Why?
|
| Patient Selection | 1 | 1995 | 592 | 0.010 |
Why?
|
| Muscles | 1 | 1971 | 158 | 0.010 |
Why?
|
| Arginine | 1 | 1971 | 102 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1971 | 150 | 0.010 |
Why?
|
| Obesity | 1 | 1998 | 1076 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1992 | 601 | 0.010 |
Why?
|
| Veterans | 1 | 1997 | 904 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1969 | 276 | 0.010 |
Why?
|
| Phospholipids | 1 | 1988 | 108 | 0.000 |
Why?
|
| Glycosylation | 1 | 1988 | 185 | 0.000 |
Why?
|
| Mannose | 1 | 1968 | 9 | 0.000 |
Why?
|
| Leucine | 1 | 1968 | 41 | 0.000 |
Why?
|
| Secretory Rate | 1 | 1967 | 11 | 0.000 |
Why?
|
| Pancreatectomy | 1 | 1968 | 129 | 0.000 |
Why?
|
| Urea | 2 | 1957 | 51 | 0.000 |
Why?
|
| Adenoma | 1 | 1968 | 132 | 0.000 |
Why?
|
| Blood Proteins | 1 | 1986 | 94 | 0.000 |
Why?
|
| Glycation End Products, Advanced | 1 | 1986 | 125 | 0.000 |
Why?
|
| Patient Compliance | 1 | 1986 | 402 | 0.000 |
Why?
|
| Night Care | 1 | 1980 | 4 | 0.000 |
Why?
|
| Sleep | 1 | 1980 | 263 | 0.000 |
Why?
|
| Autopsy | 1 | 1972 | 56 | 0.000 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1972 | 20 | 0.000 |
Why?
|
| Shock | 1 | 1972 | 28 | 0.000 |
Why?
|
| Kidney | 1 | 1972 | 945 | 0.000 |
Why?
|
| Lung | 1 | 1972 | 849 | 0.000 |
Why?
|